Kuros BiosciencesCSBTF 71 Cyclically Adjusted PS Ratio is 19.42 as of Jul. 03, 2026, which is 3635% above its 10-year median of 0.52. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.40 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 525 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 96.76% on this metric.
The historical rank and industry rank for Kuros Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:
CSBTF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.52 Max: 33.57
Current: 21.79
During the past 13 years, Kuros Biosciences's highest Cyclically Adjusted PS Ratio was 33.57. The lowest was 0.02. And the median was 0.52.
CSBTF's Cyclically Adjusted PS Ratio is ranked worse than 96.76% of 525
companies
in the Medical Devices & Instruments industry
Industry Median: 2.22
vs CSBTF: 21.79
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Kuros Biosciences's adjusted revenue per share data of for the fiscal year that ended in Dec25 was $4.429. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.17 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Kuros Biosciences (OTCPK:CSBTF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Kuros Biosciences Cyclically Adjusted PS Ratio Related Terms
Kuros Biosciences Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences Cyclically Adjusted PS Ratio Chart
CSBTF vs ABT, SYK, MDT: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, Kuros Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Cyclically Adjusted PS Ratio falls into.
Kuros Biosciences Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Kuros Biosciences's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 19.42 mean?
Kuros Biosciences (CSBTF) has a Cyclically Adjusted PS Ratio of 19.42 as of Jul. 03, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kuros Biosciences and its competitors. This is 3635% above median its historical median of 0.52. Over the past decade, Kuros Biosciences' Cyclically Adjusted PS Ratio has ranged from 0.02 to 33.57. According to the industry distribution chart, Kuros Biosciences ranks #508 out of 525 companies in the Medical Devices & Instruments industry, placing it in the top 96.8%.
Is Kuros Biosciences' Cyclically Adjusted PS Ratio too high?
Kuros Biosciences' current Cyclically Adjusted PS Ratio of 19.42 is 3635% above median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 33.57. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.22. Kuros Biosciences' value of 19.42 is 774.8% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #508 out of 525 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Cyclically Adjusted PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #508 out of 525 companies for Cyclically Adjusted PS Ratio. This places Kuros Biosciences in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.22. Kuros Biosciences' value of 19.42 is 774.8% above this benchmark. Historically, Kuros Biosciences' own Cyclically Adjusted PS Ratio has ranged from 0.02 to 33.57 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 2.22, Kuros Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.22, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Cyclically Adjusted PS Ratio of 19.42 is 774.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Cyclically Adjusted PS Ratio is 19.42, which is 3635% above median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.40, compared to a current price of $22.72 — trading 58.2% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 19.42, which is 3635% above median its 10-year median of 0.52 and 774.8% above the Medical Devices & Instruments industry median of 2.22. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Cyclically Adjusted PS Ratio is 19.42 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.2% below its estimated GF Value™ of $54.40.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Cyclically Adjusted PS Ratio: 19.42 (3635% above median its 10-year median of 0.52)
GF Value™: $54.40 vs. price of $22.72 (58.2% below fair value)
Industry Position: 774.8% above the Medical Devices & Instruments median (#508 of 525)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
